Premium
Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers
Author(s) -
SELS J. P. J. E.,
NAUTA J. J. P.,
MENHEERE P. P. C. A.,
WOLFFENBUTTEL B. H. R.,
NIEUWENHUIJZEN KRUSEMAN A. C.
Publication year - 1996
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1996.tb00015.x
Subject(s) - placebo , medicine , concomitant , endocrinology , area under the curve , insulin , gastroenterology , pathology , alternative medicine
In this double‐blind, cross‐over, placebo‐controlled, randomized study, possible extraintestinal effects of miglitol, an absorbable α‐glucosidase inhibitor, were investigated. Sixteen healthy male volunteers underwent two 75 g oral glucose tolerance tests with concomitant administration of miglitol or placebo. Peak and post‐peak areas under the curve values for blood glucose, serum insulin and serum C‐peptide after miglitol were not different from those found after placebo. The post‐peak AUC‐ratio (AUC (peak, 180 min) on miglitol/AUC (peak, 180 min) on placebo) was for glucose 1.15 (CI 0.94–1.40, P =0.16), for insulin 1.12 (CI 0.95–1.33, P =0.17) and for C‐peptide 0.98 (CI 0.81–1.18, P =0.82). It is concluded that miglitol exerts no clinically relevant extraintestinal effects on glucose control.